FDA Approves Merck’s DIFICID® (fidaxomicin) to Treat Clostridioides difficile (C. diff. ) in Children Aged Six Months and Older
FDA Approves Merck’s DIFICID® (fidaxomicin) to Treat Clostridioides difficile (C. diff. ) in Children Aged Six Months and Older
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced on January 27, 2020, that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for DIFICID® (fidaxomicin) for oral suspension, and a supplemental New Drug Application (sNDA) for DIFICID tablets for the treatment of Clostridioides (formerly Clostridium) difficile-associated diarrhea…
View On WordPress












